Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Metsera, Inc.

Get SEC filing alerts via email and in your feed for Metsera, Inc.

MTSR

Metsera, Inc.

About Metsera, Inc.

Metsera, Inc. is a biotechnology company developing next-generation injectable and oral NuSH analog peptides to treat obesity and overweight. Its platform technologies enable scalable, long-acting, and tolerable therapies, including GLP-1, amylin, GIP, glucagon, and PYY analogs. Focused on improving efficacy, convenience, and manufacturing scalability, the company aims to address limitations of current treatments and expand options for chronic weight management.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Metsera, Inc.

1
1
Metsera, Inc. Metsera Reports $116.2M Net Loss, Enters Merger Agreement with Pfizer

Via official filing (AI summary) | 7 months ago | 0 comments

2
1
Metsera, Inc. Metsera Reports $68.7 Million Net Loss in Q2 2025, Cash Reserves Increase to $530.9 Million

Via official filing (AI summary) | 11 months ago | 0 comments

3
1
Metsera, Inc. Metsera Reports $76.6 Million Net Loss and IPO Proceeds of $288.4 Million

Via official filing (AI summary) | about 1 year ago | 0 comments